

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12176 A3

(51) International Patent Classification⁷: **A61K 31/39**,
31/16, 31/35, 31/42, 31/425, 31/44, 31/445, 31/47, 31/50,
31/505, 31/535

(21) International Application Number: PCT/EP00/07917

(22) International Filing Date: 8 August 2000 (08.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99116026.8 16 August 1999 (16.08.1999) EP

(71) Applicant (*for all designated States except US*):
SANOFI-SYNTHELABO [FR/FR]; 174, avenue de
France, F-75013 Paris (FR).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **ROSENZWEIG,**
Pierre [FR/FR]; 117, avenue de Choisy, F-75013 Paris
(FR).

(74) Agent: **THOURET-LEMAITRE, Elisabeth;**
Sanofi-Synthelabo, 174, avenue de France, F-75013
Paris (FR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(88) Date of publication of the international search report:
21 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF MONOAMINE OXIDASE INHIBITORS FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF OBESITY

(57) Abstract: The present invention relates to the use of reversible selective inhibitors of monoamine oxidase A (MAO-A), reversible selective inhibitors of monoamine oxidase B (MAO-B) or reversible mixed inhibitors of MAO-A and MAO-B in the manufacture of drugs intended for the treatment of obesity.

WO 01/12176 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/07917

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/39 A61K31/16 A61K31/35 A61K31/42 A61K31/425
A61K31/44 A61K31/445 A61K31/47 A61K31/50 A61K31/505
A61K31/535

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, MEDLINE, BIOSIS, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 13768 A (LECLERC ODILE ;JEGHAM SAMIR (FR); PUECH FREDERIC (FR); SYNTHELABO) 17 April 1997 (1997-04-17) cited in the application abstract page 34, line 7,8 page 41, paragraph 2	1-4,12
X	WO 96 38444 A (SYNTHELABO ;JEGHAM SAMIR (FR); PUECH FREDERIC (FR); BURNIER PHILIP) 5 December 1996 (1996-12-05) cited in the application abstract page 24, line 1 -page 25, line 19; example 7	1,2,4,6,12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

24 October 2001

Date of mailing of the international search report

02/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tél. (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

A. Jakobs

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/07917

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 699 680 A (SYNTHELABO) 6 March 1996 (1996-03-06) cited in the application table 1, entry 52-57 page 24, line 1 - page 25, line 19; example 7 ---	3
X	DE 30 15 360 A (MERRELL TORAUDE & CO) 6 November 1980 (1980-11-06) page 11, paragraph 2 - page 12, paragraph 2; example 7 page 22, paragraph 2 - paragraph 2; example 7 ---	1, 2, 4, 7, 12
X	US 3 466 236 A (HOSTETTLER HANS U) 9 September 1969 (1969-09-09) column 1, line 68-71 - paragraph 2; example 7 ---	1, 2, 4, 7, 12
X	US 3 153 092 A (A. BURGER) 13 October 1964 (1964-10-13) column 1, line 10-36 - paragraph 2; example 7 ---	1, 2, 4, 7, 12
X	ZAHM P. ET AL: "Twelve-month oral toxicity study of lazabemide in dogs." JAPANESE PHARMACOLOGY AND THERAPEUTICS, (1994) 22/SUPPL. 11 (105-143)., XP000879086 abstract paragraph 2; example 7 ---	1, 2, 4, 5, 7, 12
X	LIEBOWITZ M R ET AL: "Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders." ACTA PSYCHIATRICA SCANDINAVICA. SUPPLEMENTUM, (1990) 360 29-34. REF: 43, XP000879199 abstract paragraph 2; example 7 page 30, column 2, paragraph 3 - page 31, column 1, paragraph 2; example 7 ---	1, 2, 4, 7, 12
X	KENNEDY S H ET AL: "Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine." JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, (1993 DEC) 13 (6) 415-22., XP000879189 abstract paragraph 2; example 7 ---	1, 2, 4, 8, 12
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/07917

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PRINGUEY D. ET AL: "'Antidepressants!. ANTIDEPRESSEURS." REVUE DU PRATICIEN, (15 JAN 1999) 49/2 (209-214)., XP000879200 abstract paragraph 2; example 7; table 1 page 209, column 2, paragraph 2 - paragraph 2; example 7; table 1 ---</p>	1,2,4,8, 12
X	<p>THIEL A.: "'Is psychopharmacotherapy necessary in anorexia and bulimia nervosa?!. SIND PSYCHOPHARMAKA FUR DIE BEHANDLUNG DER ANOREXIA UND BULIMIA NERVOSA NOTWENDIG?." PPMP PSYCHOTHERAPIE PSYCHOSOMATIK MEDIZINISCHE PSYCHOLOGIE, (1997) 47/9-10 (332-345)., XP000879185 abstract paragraph 2; example 7; table 3 ---</p>	1,2,4,8, 12
X	<p>BENEDETTI M.S. ET AL: "Monoamine oxidase: From physiology and pathophysiology to the design and clinical application of reversible inhibitors." ADVANCES IN DRUG RESEARCH, (1992) 23/- (65-125)., XP000879188 page 90, paragraph 2 -page 91, paragraph 1; example 7; table 3 page 98, paragraph 1 -page 103, paragraph 2; example 7; table 3 page 108, paragraph 1 - paragraph 2; example 7; table 3 ---</p>	1,2,4,8, 12
X	<p>PRIEST, R. G. (1) ET AL: "Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders." ACTA PSYCHIATRICA SCANDINAVICA, (1995) VOL. 91, NO. SUPPL. 386, PP. 40-43., XP000879201 abstract paragraph 2; example 7; table 3 ---</p>	1,2,4,8, 12
X	<p>WHITTAL M.C. ET AL: "Bulimia nervosa: A meta-analysis of psychosocial and pharmacological treatments." BEHAVIOR THERAPY, (1999) 30/1 (117-135)., XP000879168 abstract paragraph 2; example 7; table 1 ---</p>	1,2,4,8, 12
	<p>---</p> <p>---/---</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/07917

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>REYNAERT C. ET AL: "Do new antidepressants influence body weight ? Comparing moclobemide to fluoxetine." EUROPEAN NEUROPSYCHOPHARMACOLOGY, (1993) 3/3 (354)., XP000879190 page 354, paragraphs 5,6 - paragraph 2; example 7; table 1 -----</p>	<p>1,2,4,8, 12</p>

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Present claims 1,2,4,7,12 relate to a use/product defined by reference to a desirable characteristic or property, namely reversible selective or reversible mixed monoamine oxidase A and/or B inhibitors.

The claims cover the use of all products/compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products/compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product/compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products/compounds specifically mentioned in the claims with due regard to the general idea underlying the present invention(s).

A compound or group of compounds is not sufficiently defined only by its pharmacological parameters or properties: for a fully valid definition of a compound or a group of compounds, a structural definition is needed. A complete search is virtually impossible because it is not exhaustively known which chemical compounds are comprised by the scope of the claims encompassing reversible selective or reversible mixed monoamine oxidase A and/or B inhibitors in general.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/07917

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9713768	A	17-04-1997	FR 2739856 A1	18-04-1997
			FR 2751651 A1	30-01-1998
			FR 2751653 A1	30-01-1998
			AU 7135996 A	30-04-1997
			EP 0891358 A1	20-01-1999
			WO 9713768 A1	17-04-1997
			JP 11513400 T	16-11-1999
			US 5969146 A	19-10-1999
			ZA 9608568 A	13-05-1997
WO 9638444	A	05-12-1996	FR 2734820 A1	06-12-1996
			FR 2734821 A1	06-12-1996
			AT 184005 T	15-09-1999
			AU 699367 B2	03-12-1998
			AU 6128896 A	18-12-1996
			BR 9608896 A	29-06-1999
			CA 2223011 A1	05-12-1996
			CN 1191534 A	26-08-1998
			CZ 9703784 A3	15-04-1998
			DE 69604071 D1	07-10-1999
			DE 69604071 T2	06-04-2000
			DK 835254 T3	27-03-2000
			EP 0835254 A1	15-04-1998
			ES 2138346 T3	01-01-2000
			WO 9638444 A1	05-12-1996
			GR 3031710 T3	29-02-2000
			HU 9901349 A2	30-08-1999
			IL 118542 A	06-12-2000
			JP 11507330 T	29-06-1999
			NO 975530 A	02-02-1998
			NZ 310487 A	28-05-1999
			PL 323673 A1	14-04-1998
			SK 161497 A3	06-05-1998
			US 5843975 A	01-12-1998
			ZA 9604563 A	12-12-1996
EP 0699680	A	06-03-1996	FR 2724171 A1	08-03-1996
			AT 190311 T	15-03-2000
			AU 687591 B2	26-02-1998
			AU 3041595 A	21-03-1996
			CN 1128763 A ,B	14-08-1996
			CZ 9502262 A3	13-03-1996
			DE 69515402 D1	13-04-2000
			DE 69515402 T2	19-10-2000
			DK 699680 T3	21-08-2000
			EP 0699680 A1	06-03-1996
			ES 2145886 T3	16-07-2000
			FI 954141 A	06-03-1996
			GR 3033554 T3	29-09-2000
			HU 73435 A2	29-07-1996
			IL 115276 A	06-12-1998
			JP 8099881 A	16-04-1996
			NO 953458 A	06-03-1996
			NZ 272920 A	25-03-1998
			PL 310273 A1	18-03-1996
			PT 699680 T	31-08-2000
			RU 2141482 C1	20-11-1999
			SI 699680 T1	31-10-2000

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/07917

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0699680	A		SK 108995 A3	05-06-1996
			US 5641785 A	24-06-1997
			ZA 9507414 A	15-04-1996
DE 3015360	A	06-11-1980	AU 5550780 A	30-10-1980
			BE 882104 A4	01-07-1980
			DE 3015360 A1	06-11-1980
			DE 3015373 A1	06-11-1980
			DK 180980 A	27-10-1980
			ES 490440 D0	01-04-1981
			ES 8104183 A1	01-07-1981
			FR 2457277 A2	19-12-1980
			GB 2048875 A	17-12-1980
			IT 1143941 B	29-10-1986
			JP 55145641 A	13-11-1980
			NL 8002418 A	28-10-1980
			NO 801210 A	27-10-1980
			SE 8003117 A	27-10-1980
			ZA 8001117 A	25-02-1981
US 3466236	A	09-09-1969	NONE	
US 3153092	A	13-10-1964	GB 950388 A	26-02-1964